The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung cancer (ES-SCLC).
Histologically or cytologically confirmed first-line (1L), extensive-stage (ES) small cell lung cancer (SCLC)
Must be eligible to receive a platinum-based chemotherapy regimen in combination with an anti-PD-L1 inhibitor.
At least one measurable lesion based on RECIST v1.1 per investigator assessment.
An Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.
Received any kind of platinum or etoposide treatment for limited stage (LS) SCLC within 6 months prior to enrollment.
Participants who have received prior topoisomerase inhibitor-based ADC therapy.
Participants with history of severe heart disease
Participants with active autoimmune diseases and inflammatory diseases,
SystImmune Inc.
Lead sponsor